{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T13:00:41Z","timestamp":1761224441020,"version":"build-2065373602"},"reference-count":49,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,2,14]],"date-time":"2018-02-14T00:00:00Z","timestamp":1518566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.drudis.2018.02.004","type":"journal-article","created":{"date-parts":[[2018,2,15]],"date-time":"2018-02-15T02:47:51Z","timestamp":1518662871000},"page":"1251-1257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Adaptive pathway development for Fabry disease: a clinical approach"],"prefix":"10.1016","volume":"23","author":[{"given":"Yvonne","family":"Schuller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten","family":"Arends","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"K\u00f6rver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirjam","family":"Langeveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla E.M.","family":"Hollak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2018.02.004_bib0005","series-title":"The Online Metabolic and Molecular Bases of Inherited Diseases","article-title":"\u03b1-Galactosidase A deficiency: Fabry disease","author":"Desnick","year":"2014"},{"key":"10.1016\/j.drudis.2018.02.004_bib0010","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/(SICI)1096-8628(19990611)84:5<420::AID-AJMG6>3.0.CO;2-Z","article-title":"Fabry disease: comparison of enzymatic, linkage, and mutation analysis for carrier detection in a family with a novel mutation (30delG)","volume":"84","author":"Ashton-Prolla","year":"1999","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.drudis.2018.02.004_bib0015","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1474-4422(06)70548-8","article-title":"CNS manifestations of Fabry\u2019s disease","volume":"5","author":"Fellgiebel","year":"2006","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.drudis.2018.02.004_bib0020","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"Schiffmann","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.drudis.2018.02.004_bib0025","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3733","article-title":"\u03b1-Galactosidase A deficiency: Fabry disease","author":"Desnick","year":"2001"},{"key":"10.1016\/j.drudis.2018.02.004_bib0030","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson\u2013Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.drudis.2018.02.004_bib0035","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s40265-017-0788-z","article-title":"Factors contributing to the efficacy\u2013effectiveness gap in the case of orphan drugs for metabolic diseases","volume":"77","author":"Schuller","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2018.02.004_bib0040","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A\u2014replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2018.02.004_bib0045","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.2006.104026","article-title":"Effects of enzyme replacement therapy on the cardiomyopathy of Anderson\u2013Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa","volume":"94","author":"Hughes","year":"2008","journal-title":"Heart"},{"key":"10.1016\/j.drudis.2018.02.004_bib0050","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2018.02.004_bib0055","unstructured":"European Medicines Agency (2017) Adaptive pathways. Available at: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/regulation\/general\/general_content_000601.jsp"},{"key":"10.1016\/j.drudis.2018.02.004_bib0060","unstructured":"European Medicines Agency (2016) Final report on the adaptive pathways pilot. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Report\/2016\/08\/WC500211526.pdf"},{"key":"10.1016\/j.drudis.2018.02.004_bib0065","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ymgme.2015.11.014","article-title":"Discontinuation of enzyme replacement therapy in Fabry disease in the Dutch cohort","volume":"117","author":"Arends","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.drudis.2018.02.004_bib0070","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2016090964","article-title":"Characterization of classical and nonclassical Fabry disease: a multicenter study","volume":"28","author":"Arends","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.drudis.2018.02.004_bib0075","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ymgme.2017.05.001","article-title":"Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease","volume":"121","author":"Arends","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.drudis.2018.02.004_bib0080","unstructured":"European Medicines Agency (2001) European Public Assessment Report Replagal. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Scientific_Discussion\/human\/000369\/WC500053608.pdf."},{"key":"10.1016\/j.drudis.2018.02.004_bib0085","unstructured":"European Medicines Agency (2001) European Public Assessment Report Fabrazyme. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Scientific_Discussion\/human\/000370\/WC500020543.pdf."},{"key":"10.1016\/j.drudis.2018.02.004_bib0090","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1750-1172-8-29","article-title":"Cost-effectiveness of enzyme replacement therapy for Fabry disease","volume":"8","author":"Rombach","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.drudis.2018.02.004_bib0095","unstructured":"European Public Assessment Report Fabrazyme \u2014 variation (2016). Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/000370\/WC500210827.pdf."},{"key":"10.1016\/j.drudis.2018.02.004_bib0100","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1651-2227.2007.00029.x","article-title":"Enzyme replacement therapy with agalsidase alfa in children with Fabry disease","volume":"96","author":"Ramaswami","year":"2007","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.drudis.2018.02.004_bib0105","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1542\/peds.2005-2895","article-title":"Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease","volume":"118","author":"Ries","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.drudis.2018.02.004_bib0110","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jpeds.2009.11.007","article-title":"Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease","volume":"156","author":"Schiffmann","year":"2010","journal-title":"J. Pediatr."},{"key":"10.1016\/j.drudis.2018.02.004_bib0115","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13023-014-0169-6","article-title":"Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study","volume":"9","author":"Schiffmann","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.drudis.2018.02.004_bib0120","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jpeds.2007.09.007","article-title":"Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease","volume":"152","author":"Wraith","year":"2008","journal-title":"J. Pediatr."},{"key":"10.1016\/j.drudis.2018.02.004_bib0125","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.drudis.2018.02.004_bib0130","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006663.pub3","article-title":"Enzyme replacement therapy for Anderson\u2013Fabry disease","volume":"2013","author":"El Dib","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.drudis.2018.02.004_bib0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173358","article-title":"Enzyme replacement therapy for Anderson\u2013Fabry disease: a complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies","volume":"12","author":"El Dib","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2018.02.004_bib0140","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2018.02.004_bib0145","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2174\/187152506778520718","article-title":"The role of ceramide trihexoside (globotriaosylceramide) in the diagnosis and follow-up of the efficacy of treatment of Fabry disease: a review of the literature","volume":"4","author":"Bekri","year":"2006","journal-title":"Cardiovasc. Hematol. Agents Med. Chem."},{"key":"10.1016\/j.drudis.2018.02.004_bib0150","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s10545-006-0484-8","article-title":"The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels","volume":"30","author":"Vedder","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.drudis.2018.02.004_bib0155","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1651-2227.2005.tb02112.x","article-title":"Is globotriaosylceramide a useful biomarker in Fabry disease?","volume":"94","author":"Young","year":"2005","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.drudis.2018.02.004_bib0160","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1750-1172-6-16","article-title":"Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders","volume":"6","author":"Hollak","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.drudis.2018.02.004_bib0165","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/S0140-6736(09)61493-8","article-title":"Enzyme replacement therapy with agalsidase alfa in patients with Fabry\u2019s disease: an analysis of registry data","volume":"374","author":"Mehta","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2018.02.004_bib0170","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ijcard.2014.09.001","article-title":"Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance","volume":"177","author":"Smid","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.drudis.2018.02.004_bib0175","first-page":"83","article-title":"Uncertain diagnosis of fabry disease in patients with neuropathic pain, angiokeratoma or cornea verticillata: consensus on the approach to diagnosis and follow-up","volume":"17","author":"van der Tol","year":"2014","journal-title":"JIMD Rep."},{"key":"10.1016\/j.drudis.2018.02.004_bib0180","first-page":"21","article-title":"Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: a Fabry outcome survey analysis","volume":"3","author":"Beck","year":"2015","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.drudis.2018.02.004_bib0185","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/gim.2013.53","article-title":"Analysis of left ventricular mass in untreated men and in men treated with agalsidase-beta: data from the Fabry Registry","volume":"15","author":"Germain","year":"2013","journal-title":"Genet. Med."},{"key":"10.1016\/j.drudis.2018.02.004_bib0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jmedgenet-2013-101857","article-title":"A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance","volume":"51","author":"van der Tol","year":"2014","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.drudis.2018.02.004_bib0195","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.amjcard.2005.11.087","article-title":"Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry\u2019s cardiomyopathy","volume":"97","author":"Beer","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.drudis.2018.02.004_bib0200","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2018.02.004_bib0205","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","article-title":"Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document","volume":"10","author":"Biegstraaten","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.drudis.2018.02.004_bib0210","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.2215\/CJN.04340510","article-title":"Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry","volume":"5","author":"Wanner","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.drudis.2018.02.004_bib0215","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1136\/bmj.j1680","article-title":"Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review","volume":"357","author":"Pease","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.drudis.2018.02.004_bib0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182379","article-title":"Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: analysis of prognostic factors","volume":"12","author":"Arends","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2018.02.004_bib0225","series-title":"5th HTA Network Meeting","article-title":"PARENT \u2014 Joint action: cross-border patient registries initiative","author":"Magajne","year":"2015"},{"key":"10.1016\/j.drudis.2018.02.004_bib0230","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1001\/jamainternmed.2015.5868","article-title":"Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals","volume":"175","author":"Kim","year":"2015","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.drudis.2018.02.004_bib0235","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/cpt.174","article-title":"Use of the conditional marketing authorization pathway for oncology medicines in Europe","volume":"98","author":"Hoekman","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2018.02.004_bib0240","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/pds.2209","article-title":"European Medicines Agency review of post-authorisation studies with implications for the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance","volume":"20","author":"Blake","year":"2011","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.drudis.2018.02.004_bib0245","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13023-016-0383-5","article-title":"Position statement on the role of healthcare professionals, patient organizations and industry in European Reference Networks","volume":"11","author":"Hollak","year":"2016","journal-title":"Orphanet J. Rare Dis."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644617304282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644617304282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:34:40Z","timestamp":1761222880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644617304282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1359644617304282"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2018.02.004","relation":{},"ISSN":["1359-6446"],"issn-type":[{"type":"print","value":"1359-6446"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adaptive pathway development for Fabry disease: a clinical approach","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2018.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}